Muscle Strength, Functional Capacity, Respiratory Function and Quality Of Life In Cystic Fibrosis Patients
Upper Extremity Muscle Strength and Endurance, Functional Capacity, Respiratory Function and Quality of Life in Child and Adolescent With Cystic Fibrosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Şahinbey
-
Gaziantep, Şahinbey, Turkey
- Hasan Kalyoncu Universty
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals diagnosed with CF with clinical findings and gene mutations consistent with CF, having over 60mEq / L in two measurements in sweat chlorine examinations
Exclusion Criteria:
- Patients who did not exacerbate the disease in the last four weeks, who had good cooperation and did not have any orthopedic problems in the hand-shoulder-arm complex were included.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Cystic fibrosis
|
Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Forced Expiratory Volume in 1 Second (FEV1)
Time Frame: 1 day
|
Pulmonary function tests were evaluated with a spirometer.
It is the volume of air released in the first second from the beginning of the difficult vital capacity maneuver.
In general, it gives information about the restriction in major airlines.
FEV1 / FVC ratio decrease shows obstruction, FEV1 shows the severity of obstruction.
|
1 day
|
|
Six-minute walk test
Time Frame: 1 day
|
In the 6-minute walk test (6MWT), subjects were asked to walk as fast as they could walk within 6 minutes along a 30-meter straight corridor.
The test was performed twice within the same day at intervals of half an hour.
The longer distance value for each patient from the two tests used was used for statistical analysis.
|
1 day
|
|
Forced Vital Capacity (FVC)
Time Frame: 1 day
|
Pulmonary function tests were evaluated with a spirometer.
It is the volume of air that comes out with rapid and powerful exhalation following deep inspiratory.
Healthy people can normally extract 80 percent of their lung volume in 6 seconds or less
|
1 day
|
|
Peak Expiratory Flow (PEF)
Time Frame: 1 day
|
Pulmonary function tests were evaluated with a spirometer.
It is measured by the maximum exhalation maneuver following the maximum inspiration.
It gives information about obstruction in large airways.
|
1 day
|
|
Upper Limb Muscle Strength
Time Frame: 1 day
|
Evaluation of peripheral muscle strength Deltoideus (shoulder abduction), Biceps Brachii (elbow flexion) muscles were evaluated with a digital dynamometer (Lafeyette manual muscle tester, U.S.A).
Handgrip strength was measured by a hand dynamometer (Baseline LITE hand dynamometer, U.S.A).
In each muscle test, the right and left sides were evaluated separately and repeated three times and the best values obtained were recorded in Newton (N).
Arithmetic means of the right and left sides were used for statistical analysis.
|
1 day
|
|
Upper Limb muscular endurance
Time Frame: 1 day
|
The arm pull-up test was used in the evaluation of muscular endurance.
|
1 day
|
|
Ouality of Life
Time Frame: 1 day
|
Cystic Fibrosis Questionnaire-Revised (CFQ-R) was used to evaluate the quality of life.
There are four CFQ-R questionnaires for parents of children aged 6 years and over, three different age groups [6-10, 12-13, and over).
The child's version of CFQ-R consists of 35 questions in 8 parts, Physical Functioning, Emotional Functioning, Social Functioning, Body Image, Eating Disturbances, Treatment Burden, Respiratory symptoms, and Digestive symptoms.
Its values range from 0 to 100 points and the higher the score, the better quality of life.
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Çağtay maden, MSc, Pt, Hasan Kalyoncu University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016/06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
NCT03273959UnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With Exacerbation
-
NCT07223255RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Gastrointestinal Disease
-
NCT07616375RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT07245407RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT07484607RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Pulmonary Exacerbation
-
NCT07289464RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT03939065TerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children
-
NCT04602468Active, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver Disease
-
NCT06084468Active, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease
-
NCT06940531RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Pulmonary Exacerbation
Clinical Trials on cystic fibrosis
-
NCT00004806Completed
-
NCT01379040CompletedCystic Fibrosis | Pseudomonas Aeruginosa
-
NCT02003079Completed
-
NCT02449785Completed
-
NCT01013896Completed
-
NCT03462056Completed
-
NCT00221572Completed
-
NCT06984679RecruitingCystic Fibrosis (CF) | Cystic Fibrosis in Children
-
NCT06012084CompletedCystic Fibrosis | Mental Health | Siblings | Internet-based Intervention
-
NCT06020274Not yet recruitingMental Health | Cystic Fibrosis in Children | Siblings | Internet-based Intervention